{"id":511,"date":"2025-11-18T20:50:40","date_gmt":"2025-11-19T00:50:40","guid":{"rendered":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=511"},"modified":"2025-11-18T20:50:41","modified_gmt":"2025-11-19T00:50:41","slug":"vicki-norton-to-speak-at-personalized-cancer-vaccine-summit","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2025\/11\/18\/vicki-norton-to-speak-at-personalized-cancer-vaccine-summit\/","title":{"rendered":"Vicki Norton to Speak at Personalized Cancer Vaccine Summit"},"content":{"rendered":"\n<p>Duane Morris Partner <a href=\"https:\/\/www.duanemorris.com\/attorneys\/vickignorton.html\">Vicki G. Norton, Ph.D<\/a>., will be speaking at the Personalized Cancer Vaccine Summit in Boston on Thursday, November 20. She will be on the panel &#8220;Health Economics, IP &amp; Early Access: Navigating Legal Grey Zones in the Race to Personalized Cancer Vaccines.&#8221; The panel will discuss: <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li> How emerging legal frameworks, such as Montana&#8217;s Right To Try, could impact patient access to unapproved personalized vaccines and what that means for regulatory strategy.<\/li>\n\n\n\n<li>Balancing IP protection vs. platform flexibility in an era where proprietary algorithms, tumor-specific libraries, and bioinformatic tools are central to value creation.<\/li>\n\n\n\n<li>The role of patent exclusivity, trade secrets, and data protection in enabling commercial viability for PCVs &#8211; especially when facing fragmented regulatory landscapes.<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Duane Morris Partner Vicki G. Norton, Ph.D., will be speaking at the Personalized Cancer Vaccine Summit in Boston on Thursday, November 20. She will be on the panel &#8220;Health Economics, IP &amp; Early Access: Navigating Legal Grey Zones in the Race to Personalized Cancer Vaccines.&#8221; The panel will discuss:<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[10,274],"ppma_author":[521],"class_list":["post-511","post","type-post","status-publish","format-standard","hentry","category-general","tag-intellectual-property","tag-patents"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=511"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/511\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=511"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}